Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential-Reference-Cited by-同舟云学术

Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential

Published:2018-09-28 Issue:12 Volume:32 Page:1159-1171
ISSN:1172-7047
Container-title:CNS Drugs
language:en
Short-container-title:CNS Drugs

Author:

Klistorner Alexander,Chai Yi,Leocani Letizia,Albrecht Philipp,Aktas Orhan,Butzkueven Helmut,Ziemssen Tjalf,Ziemssen Focke,Frederiksen Jette,Xu Lei,Cadavid Diego,Butzkueven Helmut,Garrick Ray,Vanopdenbosch Ludo,Frederiksen Jette,Aktas Orhan,Albrecht Philipp,Ziemssen Focke,Ziemssen Tjalf,Comi Giancarlo,Dalmau Bernardo Sánchez,Andersson Magnus,Plant Gordon T.,Matthews Tim,Williams Graeme,

Funder

Biogen

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Psychiatry and Mental health,Clinical Neurology

Link

https://link.springer.com/article/10.1007/s40263-018-0575-8/fulltext.html

Reference44 articles.

1. Mi S, Pepinsky RB, Cadavid D. Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic. CNS Drugs. 2013;27:493–503.

2. Tran JQ, Rana J, Barkhof F, Melamed I, Gevorkyan H, Wattjes MP, et al. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflamm. 2014;1:e18.

3. Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, RENEW Study Investigators, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16:189–99.